TB-500 vs GHK-Cu
Head-to-head comparison of TB-500 and GHK-Cu for research applications. Both peptides are studied for various research applications, but they differ significantly in mechanism, evidence level, and dosing protocols.
Side-by-Side Comparison
| Attribute | Tb 500 | Ghk Cu |
|---|---|---|
| Category | Healing & Recovery | Skin & Tissue Repair |
| Mechanism | TB-500 works primarily through actin sequestration — it binds to G-actin monomers, preventing premature polymerization, which allows repair cells to migrate rapidly to injured areas. | GHK-Cu chelates copper(II) ions via its histidine residue and delivers bioavailable copper directly to cells, preventing free copper oxidative damage. |
| Evidence Rating | D — Preclinical | F — No Regulatory Activity |
| Clinical Status | Research-only / Veterinary use in some jurisdictions. Limited human RCTs completed. | Available in cosmetic formulations; no drug approval |
| Safety Profile | A safety-focused RCT in 40 healthy adults (2010) was designed expressly to assess safety and found minimal adverse effects with synthetic thymosin-beta 4; No significant safety concerns in published human studies to date; TB-500 administration has produced minimal side effects in animal and human studies alike | Safety profile is excellent with minimal side effects reported in decades of cosmetic use and clinical research (PMID: 29986520); Topical forms are generally well-tolerated; mild skin irritation rare and typically limited to very sensitive skin |
| Route | Subcutaneous | Subcutaneous, Topical (cream/serum), or Intradermal (microneedling) |
| Dose Range | 500–1000 mcg/day SC (~5 mg/week average) | SC: 50–200 mcg/day; Topical: 1–4% cream or serum applied to target area |
| Frequency | Once daily | SC: Once daily; Topical: 1–2x daily |
| Molecular Weight | ~889 g/mol | ~403.9 g/mol |
| Half-Life | <2 hours plasma half-life; tissue effects persist 2–3 days | ~30 minutes plasma |
Overview
TB-500 and GHK-Cu are both research peptides studied across multiple applications. This comparison examines their mechanisms, evidence base, dosing protocols, and safety profiles to help researchers understand the key differences and overlaps.
TB-500 — Mechanism & Evidence
TB-500 is a synthetic fragment of thymosin beta-4 (Tβ4), a naturally occurring 43-amino-acid peptide found throughout human tissues. TB-500 contains the active healing region (sequence: Ac-LKKTETQ, MW ~889 g/mol) responsible for cell migration and tissue repair. It has a handful of human RCTs for wound healing and dry eye, plus a dedicated safety trial in 40 healthy adults showing minimal adverse effects. Despite this, it remains unapproved for human therapeutic use in all major markets and is banned by WADA and in horse racing.
Key claims: Accelerates wound healing; Reduces inflammation; Promotes cardiac repair.
GHK-Cu 50mg
50mg
GHK-Cu — Mechanism & Evidence
GHK-Cu is a naturally occurring copper-binding tripeptide (glycyl-L-histidyl-L-lysine) found in human plasma, saliva, and urine. First discovered by Dr. Loren Pickart in 1973, plasma levels average 200 ng/mL at age 20 but decline to ~80 ng/mL by age 60. It has been extensively studied for wound healing, collagen synthesis, skin regeneration, and gene modulation, with decades of cosmetic use and a broad safety profile. Molecular weight is approximately 340 g/mol (as the copper complex), with the formula C14H24N6O4Cu.
Key claims: Improves skin firmness and elasticity; Promotes wound healing; Reduces fine lines and wrinkles.
Shared Research Applications
These peptides target different research areas. TB-500 focuses on Injury Recovery, Anti-Inflammatory, while GHK-Cu targets Skin Health, Anti-Aging, Wound Healing.
Safety Considerations
TB-500: A safety-focused RCT in 40 healthy adults (2010) was designed expressly to assess safety and found minimal adverse effects with synthetic thymosin-beta 4 No significant safety concerns in published human studies to date; TB-500 administration has produced minimal side effects in animal and human studies alike Common anecdotal side effects: injection site pain/redness, lightheadedness, mild headache, nausea, fatigue
GHK-Cu: Safety profile is excellent with minimal side effects reported in decades of cosmetic use and clinical research (PMID: 29986520) Topical forms are generally well-tolerated; mild skin irritation rare and typically limited to very sensitive skin Injectable forms: mild injection site reactions, lightheadedness, nausea, flu-like symptoms possible; rotate injection sites to reduce local irritation
Shop Research Peptides
GHK-Cu 50mg
50mg
BPC-157 5mg
5mg
Retatrutide 20mg
20mg
Retatrutide 10mg
10mg
Tesamorelin 10mg
10mg
BPC-157 10mg
10mg
Tirzepatide 10mg
10mg
Quality Documentation
Review batch documentation before making research purchasing decisions. Volta pairs product education with COA literacy so researchers can evaluate purity, identity, lot details, and testing context.
Product cards on this page link to current catalog entries and available quality documentation.
Related Research News
GHK-Cu in Research: Reconstitution, Stability, and Handling Guide
This guide covers the essentials of working with GHK-Cu in a research setting, from reconstitution math and solvent choice to stability and purity considerations. Learn how to handle copper peptides correctly and what to verify before starting a study.
TB-500 vs BPC-157: Evidence, Dosing, Safety Compared
This reference compares TB-500 and BPC-157 across mechanism, dosing, evidence, safety, and pharmacokinetics, highlighting the thin comparative evidence and the need for further study.
TB-500 and the Brain: Thymosin Beta-4 in Neurological Research
Explore the preclinical evidence for TB-500 (Thymosin Beta-4) in neurological research, including mechanisms, limitations, and safety.
Peptide Tools
Follow Research Updates
Get new research pages, product updates, tool releases, and quality resources from Volta.
Subscribe